Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal
June 30, 2023 at 10:30 AM EDT
Bausch + Lomb's stock leapt Friday, after the eye-health products company announced a $2.5 billion deal to buy Novartis' "dry eye" treatment Xiidra.
